Provided by Tiger Fintech (Singapore) Pte. Ltd.

NeoGenomics

9.77
+0.08000.83%
Post-market: 9.770.00000.00%16:10 EDT
Volume:2.61M
Turnover:25.58M
Market Cap:1.26B
PE:-10.97
High:9.95
Open:9.69
Low:9.42
Close:9.69
52wk High:19.12
52wk Low:4.72
Shares:129.39M
Float Shares:119.99M
Volume Ratio:0.52
T/O Rate:2.17%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.8908
EPS(LYR):-0.6216
ROE:-12.99%
ROA:-3.49%
PB:1.51
PE(LYR):-15.72

Loading ...

NEO has been leading the way in the robotics field. What projects in the Robotic space are worth paying attention to?

Blockbeats
·
Yesterday

NeoGenomics to present RaDaR ST bridging study at ISLB 2025

TIPRANKS
·
Yesterday

NeoGenomics Unveils RaDaR ST Liquid Biopsy MRD Assay for Solid Tumor Detection

Reuters
·
Yesterday

Stock Track | NeoGenomics Soars 5.24% on Strong Q3 Revenue Growth and Raised Price Target

Stock Track
·
Oct 29

Stock Track | NeoGenomics Soars 5.24% on Strong Q3 Revenue Growth and Raised Price Target

Stock Track
·
Oct 29

Benchmark Co. Reaffirms Their Hold Rating on NeoGenomics (NEO)

TIPRANKS
·
Oct 29

NeoGenomics Inc. Earnings Call: Clinical Growth Amid Pharma Challenges

TIPRANKS
·
Oct 29

Strong Growth Prospects for NeoGenomics: Buy Rating with Increased Price Target

TIPRANKS
·
Oct 29

NeoGenomics’ Strong Q3 Performance and Strategic Growth Initiatives Reinforce Buy Rating

TIPRANKS
·
Oct 29

Stock Track | NeoGenomics Soars 10.24% as Q3 Results Beat Expectations, Driven by Strong Clinical Revenue Growth

Stock Track
·
Oct 28

Stock Track | NeoGenomics Soars 7.28% Pre-Market on Strong Q3 Results, Beating Revenue Estimates

Stock Track
·
Oct 28

GUIDANCE: (NEO) NeoGenomics Expects Full Year 2025 Consolidated Revenue Range $720M - $726M, vs. FactSet Est of $723.5M

MT Newswires Live
·
Oct 28

Cancer diagnostics company NeoGenomics beats Q3 estimates on clinical revenue growth

Reuters
·
Oct 28

NeoGenomics Q3 Adj. EPS $0.03 Beats $0.02 Estimate, Sales $187.797M Beat $183.770M Estimate

Benzinga
·
Oct 28

BRIEF-NeoGenomics Q3 Revenue USD 188 Million Vs. IBES Estimate USD 183.8 Million

Reuters
·
Oct 28

Neogenomics Inc: Re-Affirming Full-Year Guidance for Revenue, Net Loss and Adjusted Ebitda

THOMSON REUTERS
·
Oct 28

Neogenomics Q3 Gross Profit USD 80 Million

THOMSON REUTERS
·
Oct 28

Neogenomics Reports Third Quarter 2025 Results

THOMSON REUTERS
·
Oct 28

Craig-Hallum Remains a Buy on NeoGenomics (NEO)

TIPRANKS
·
Oct 27

Craig-Hallum Keeps Their Buy Rating on NeoGenomics (NEO)

TIPRANKS
·
Oct 23